N-(环戊基甲基)-N-乙胺 | 4492-37-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-(环戊基甲基)-N-乙胺
• 英文名称: N-(cyclopentylmethyl)-N-ethylamine
• 英文别名: N-cyclopentylmethyl ethylamine；(cyclopentylmethyl)ethylamine；cyclopentylmethylethylamine；N-(cyclopentylmethyl)ethanamine
• CAS: 4492-37-9
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: NWIOJXJADHKWLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(环戊基甲基)-N-乙胺 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.33h， 以76%的产率得到6-(cyclopentylmethyl-ethyl-amino)-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carbaldehyde
  参考文献：
  名称：

  WO2006/73973

  摘要：

  公开号：
• 作为产物：
  描述：

  N-cyclopentenoyl-ethylamine 在 lithium aluminium tetrahydride 、 水 、 sodium sulfate 作用下， 以 四氢呋喃 为溶剂， 反应 9.0h， 以40%的产率得到N-(环戊基甲基)-N-乙胺
  参考文献：
  名称：

  WO2006/73973

  摘要：

  公开号：

文献信息

• 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF
  申请人：Samumed, LLC

  公开号：US20140194441A1

  公开（公告）日：2014-07-10

  Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  揭示了用于治疗各种疾病和病理的吲唑化合物。更具体地，本公开涉及使用吲唑化合物或其类似物治疗由Wnt途径信号激活所特征的疾病（例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺部疾病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经系统疾病/疾患/疾病。还提供了治疗与Wnt相关疾病状态的方法。
• THIAZOLYL-DIHYDRO-QUINAZOLINE
  申请人：Brandl Trixi

  公开号：US20070244104A1

  公开（公告）日：2007-10-18

  Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R 1 to R 4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.

  揭示了一般式（I）的噻唑基-二氢喹唑啉化合物，其中基团R1至R4具有权利要求和说明书中给定的含义，其异构体，以及制备这些化合物的过程以及它们作为药物组成物的用途。
• [EN] NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] NOUVEAU DERIVE D'OXAZOLIDINONE COMME INHIBITEUR DE CETP, SON PROCEDE DE PREPARATION, ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT
  申请人：DONG A ST CO LTD

  公开号：WO2014157994A1

  公开（公告）日：2014-10-02

  Disclosed are a novel oxazolidinone derivative exhibiting inhibitory activity against CETP, a preparation method thereof, and a pharmaceutical composition comprising the same. Exhibiting excellent inhibitory activity against CETP, the oxazolidinone derivative can be effectively applied to the prevention or treatment of various CETP enzyme activity- or HDL cholesterol level-related diseases such as dyslipidemia, atherosclerosis, and coronary heart disease.

  本文揭示了一种新型噁唑烷酮衍生物，具有抑制CETP活性的特性，以及其制备方法和包含该衍生物的药物组合物。该噁唑烷酮衍生物表现出优异的抑制CETP活性，可有效应用于预防或治疗各种与CETP酶活性或HDL胆固醇水平相关的疾病，如脂质代谢紊乱、动脉粥样硬化和冠心病。
• NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME
  申请人：OHGIYA Tadaaki

  公开号：US20090062306A1

  公开（公告）日：2009-03-05

  A compound represented by the following general formula (I), wherein R 1 , R 2 , R 3 , R 4 and R 5 represent hydrogen atom, a halogen atom, a lower alkyl group and the like, R 6 represents an alkyl group, a cycloalkyl group and the like, R 7 and R 8 represent hydrogen atom, a lower alkyl group, a (lower cycloalkyl)(lower alkyl) group and the like, R 9 represents hydrogen atom, a halogen atom, a lower alkoxy group and the like, R 10 and R 11 represent hydrogen atom, a lower alkyl group, a lower alkoxy group, a halo(lower alkyl) group and the like, and A represents a heterocyclic ring constituted by 6 to 10 atoms, which has potent inhibitory activity on cholesterol ester transfer protein (CETP).

  通式（I）表示的化合物，其中R1、R2、R3、R4和R5表示氢原子、卤原子、低烷基基团等，R6表示烷基基团、环烷基基团等，R7和R8表示氢原子、低烷基基团、（低环烷基）（低烷基）基团等，R9表示氢原子、卤原子、低烷氧基团等，R10和R11表示氢原子、低烷基基团、低烷氧基团、卤代（低烷基）基团等，A表示由6到10个原子构成的杂环环，对胆固醇酯转移蛋白（CETP）具有强大的抑制活性。
• NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME
  申请人：OHGIYA Tadaaki

  公开号：US20090082352A1

  公开（公告）日：2009-03-26

  A compound represented by the following general formula (I), wherein R 1 , R 2 , R 3 , R 4 and R 5 represent hydrogen atom, a halo(lower alkyl) group, cyano group and the like, R 6 represents an alkyl group, a cycloalkyl group and the like, R 7 , R 8 , R 9 and R 10 represent hydrogen atom, a halogen atom, a lower alkyl group, a halo(lower alkyl) group and the like, R 11 and R 12 represent hydrogen atom, a lower alkyl group, a (lower cycloalkyl) (lower alkyl) group and the like, and R 13 represents hydrogen atom, a halogen atom, a lower alkoxy group and the like, which has potent inhibitory activity on cholesterol ester transfer protein (CETP).

  一个由以下通用公式（I）表示的化合物，其中R1、R2、R3、R4和R5代表氢原子、卤素（低烷基）基团、氰基团等，R6代表烷基基团、环烷基基团等，R7、R8、R9和R10代表氢原子、卤素原子、低烷基基团、卤素（低烷基）基团等，R11和R12代表氢原子、低烷基基团、（低环烷基）（低烷基）基团等，R13代表氢原子、卤素原子、低烷氧基团等，具有对胆固醇酯转移蛋白（CETP）具有强大抑制活性的化合物。